Veracyte is trading 5.19% higher at $46.09, with no company-specific announcement or analyst action dated September 24 identified to explain the move. - It closed at $43.82 on September 23, 2026. - Recent coverage references its September 14 acquisition of Convergent Genomics for $150 million upfront plus milestone payments; this is not a new catalyst today. - Broader biotech is down 2.04%, making sector momentum an unlikely explanation.